Potential role of anti-inflammatory HDL subclasses in metabolic unhealth/obesity

References

• Tall AR, Yvan-Charvet L, Terasaka N, et al. HDL, ABC transporters, and cholesterol efflux: implications for the treatment of atherosclerosis. Cell Metab. 2008;7(5):365–375.
   PubMed Web of Science ®Google Scholar
• Nicholls SJ, Dusting GJ, Cutri B, et al. Reconstituted High-Density lipoproteins inhibit the acute Pro-Oxidant and proinflammatory vascular changes induced by a periarterial collar in normocholesterolemic rabbits. Circulation. 2005;111(12):1543–1550.
   PubMed Web of Science ®Google Scholar
• Fotakis P, Kothari V, Thomas DG, et al. Anti-inflammatory effects of HDL (high-density lipoprotein) in macrophages predominate over proinflammatory effects in atherosclerotic plaques. Arterioscler Thromb Vasc Biol. 2019;39(12):e253–e272.
   PubMed Web of Science ®Google Scholar
• Kaji H. High-Density lipoproteins and the immune system. J Lipids. 2013;2013:684903–684908.
   PubMedGoogle Scholar
• Moradi H, Streja E, Kashyap ML, et al. Elevated high-density lipoprotein cholesterol and cardiovascular mortality in maintenance hemodialysis patients. Nephrol Dial Transplant. 2014;29(8):1554–1562.
   PubMed Web of Science ®Google Scholar
• F K. High-Density lipoprotein in chronic kidney diseases — the devil is in the detail. J Am Soc Nephrol. 2018;29:1356–1371.
   PubMed Web of Science ®Google Scholar
• Guay S-P, Brisson D, Munger J, et al. ABCA1 gene promoter DNA methylation is associated with HDL particle profile and coronary artery disease in familial hypercholesterolemia. Epigenetics. 2012;7(5):464–472.
   PubMed Web of Science ®Google Scholar
• Cheng J, Cheng A, Clifford BL, et al. MicroRNA-144 silencing protects against atherosclerosis in male, but not female mice. Arterioscler Thromb Vasc Biol. 2020;40(2):412–425.
   PubMed Web of Science ®Google Scholar
• Rosenson RS, Brewer HB, Chapman MJ, et al. HDL measures, particle heterogeneity, proposed nomenclature, and relation to atherosclerotic cardiovascular events. Clin Chem. 2011;57(3):392–410.
   PubMed Web of Science ®Google Scholar
• Woudberg NJ, Pedretti S, Lecour S, et al. Pharmacological intervention to modulate HDL: What do We target? Front Pharmacol. 2017;8:989.
   PubMed Web of Science ®Google Scholar
• Gebhard C, Rhainds D, He G, et al. Elevated level of lecithin:cholesterol acyltransferase (LCAT) is associated with reduced coronary atheroma burden. Atherosclerosis. 2018;276:131–139.
   PubMed Web of Science ®Google Scholar
• Landry YD, Denis M, Nandi S, et al. ATP-binding cassette transporter A1 expression disrupts raft membrane microdomains through its ATPase-related functions. J Biol Chem. 2006;281(47):36091–36101.
   PubMed Web of Science ®Google Scholar
• Cheng AM, Handa P, Tateya S, et al. Apolipoprotein A-I attenuates palmitate-mediated NF-κB activation by reducing Toll-like receptor-4 recruitment into lipid rafts. PLoS One. 2012;7(3):e33917.
   PubMed Web of Science ®Google Scholar
• Triolo M, Annema W, Dullaart RPF, et al. Assessing the functional properties of high-density lipoproteins: an emerging concept in cardiovascular research. Biomark Med. 2013;7(3):457–472.
   PubMed Web of Science ®Google Scholar
• Deakin SP, James RW. Genetic and environmental factors modulating serum concentrations and activities of the antioxidant enzyme paraoxonase-1. Clin Sci (Lond)). 2004;107(5):435–447.
   PubMed Web of Science ®Google Scholar
• Graner M, et al. Association of paraoxonase-1 activity and concentration with angiographic severity and extent of coronary artery disease. J Am Coll Cardiol. 2006;47(12):2429–2435.
   PubMed Web of Science ®Google Scholar
• Hahn BH, Grossman J, Ansell BJ, et al. Altered lipoprotein metabolism in chronic inflammatory states: proinflammatory high-density lipoprotein and accelerated atherosclerosis in systemic lupus erythematosus and rheumatoid arthritis. Arthritis Res Ther. 2008;10(4):213–213.
   PubMed Web of Science ®Google Scholar
• Holzer M, Wolf P, Curcic S, et al. Psoriasis alters HDL composition and cholesterol efflux capacity. J Lipid Res. 2012;53(8):1618–1624.
   PubMed Web of Science ®Google Scholar
• Nob Court E, et al. Defective antioxidative activity of small dense HDL3 particles in type 2 diabetes: relationship to elevated oxidative stress and hyperglycaemia. Diabetologia. 2005;48(3):529–538.
   PubMed Web of Science ®Google Scholar
• Ying W, Fu W, Lee YS, et al. The role of macrophages in obesity-associated islet inflammation and β-cell abnormalities. Nat Rev Endocrinol. 2020;16(2):81–90.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Muniesa P, et al. Obesity. Nat Rev Dis Primers. 2017;3:17034.
   PubMed Web of Science ®Google Scholar
• M B. Metabolically healthy obesity. Endocr Rev. 2020;41(3):405–420.
   Web of Science ®Google Scholar
• Stefan N, Schick F, Häring H. Causes, characteristics, and consequences of metabolically unhealthy normal weight in humans. Cell Metab. 2017;26(2):292–300.
   PubMed Web of Science ®Google Scholar
• Smith GI, Mittendorfer B, Klein S. Metabolically healthy obesity: facts and fantasies. J Clin Invest. 2019;129(10):3978–3989.
   PubMed Web of Science ®Google Scholar
• Eckel N, Li Y, Kuxhaus O, et al. Transition from metabolic healthy to unhealthy phenotypes and association with cardiovascular disease risk across BMI categories in 90 257 women (the nurses' health study): 30 year follow-up from a prospective cohort study. Lancet Diabetes Endocrinol. 2018;6(9):714–724.
   PubMed Web of Science ®Google Scholar
• Bell JA, Hamer M, Sabia S, et al. The natural course of healthy obesity over 20 years. J Am Coll Cardiol. 2015;65(1):101–102.
   PubMed Web of Science ®Google Scholar
• Kobiyama K, Ley K. Atherosclerosis. Circ Res. 2018;123(10):1118–1120.
   PubMed Web of Science ®Google Scholar
• González-Gil EM, C.S. C.,  J., Inflammation in metabolically healthy and metabolically abnormal adolescents: the HELENA study. Nutr Metab Cardiovasc Dis. 2018;28:77–83.
   PubMed Web of Science ®Google Scholar
• Miller WG, Myers GL, Sakurabayashi I, et al. Seven direct methods for measuring HDL and LDL cholesterol compared with ultracentrifugation reference measurement procedures. Clinical Chemistry. 2010;56(6):977–986.
   PubMed Web of Science ®Google Scholar
• Asztalos BF, Sloop CH, Wong L, et al. Two-dimensional electrophoresis of plasma lipoproteins: Recognition of new apo A-I-containing subpopulations. Biochim Biophys Acta Lipids Lipid Metab. 1993;1169(3):291–300.
   PubMed Web of Science ®Google Scholar
• Mueller O, et al. PROCAM study: risk prediction for myocardial infarction using microfluidic high-density lipoprotein (HDL) subfractionation is independent of HDL cholesterol. Clin Chem Lab Med. 2008;46(4):490–498.
   PubMed Web of Science ®Google Scholar
• Ene-Iordache B, Perico N, Bikbov B, et al. Chronic kidney disease and cardiovascular risk in six regions of the world (ISN-KDDC): a cross-sectional study. Lancet Glob Health. 2016;4(5):e307–e319.
   PubMed Web of Science ®Google Scholar
• Grundy SM, Cleeman JI, Daniels SR, National Heart, Lung, and Blood Institute, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005;112(17):2735–2752.,
   PubMed Web of Science ®Google Scholar
• Stefan N, Häring H, Schulze MB. Metabolically healthy obesity: the low-hanging fruit in obesity treatment? Lancet Diabetes Endocrinol. 2018;6(3):249–258.
   PubMed Web of Science ®Google Scholar
• Singh IM, Shishehbor MH, Ansell BJ. High-density lipoprotein as a therapeutic target: a systematic review. JAMA. 2007;298(7):786–798.
   PubMed Web of Science ®Google Scholar
• Stadler JT, Lackner S, Mörkl S, et al. Obesity affects HDL metabolism, composition and subclass distribution. Biomedicines. 2021;9(3):242.
   PubMed Web of Science ®Google Scholar
• Marsche G, et al. Current understanding of the relationship of HDL composition, structure and function to their cardioprotective properties in chronic kidney disease. Biomolecules. 2020;10(9):1348.
   Web of Science ®Google Scholar
• von Eckardstein A, Nofer JR, Assmann G. High density lipoproteins and arteriosclerosis. Role of cholesterol efflux and reverse cholesterol transport. Arterioscler Thromb Vasc Biol. 2001;21(1):13–27.
   PubMed Web of Science ®Google Scholar
• Rye K, Clay MA, Barter PJ. Remodelling of high density lipoproteins by plasma factors. Atherosclerosis. 1999;145(2):227–238.
   PubMed Web of Science ®Google Scholar
• Lewis GF, Rader DJ. New insights into the regulation of HDL metabolism and reverse cholesterol transport. Circ Res. 2005;96(12):1221–1232.
   PubMed Web of Science ®Google Scholar
• Rashid S, Watanabe T, Sakaue T, et al. Mechanisms of HDL lowering in insulin resistant, hypertriglyceridemic states: the combined effect of HDL triglyceride enrichment and elevated hepatic lipase activity. Clin Biochem. 2003;36(6):421–429.
   PubMed Web of Science ®Google Scholar
• Graham TE, Yang Q, Blüher M, et al. Retinol-binding protein 4 and insulin resistance in lean, obese, and diabetic subjects. N Engl J Med. 2006;354(24):2552–2563.
   PubMed Web of Science ®Google Scholar
• Yang Q, Graham TE, Mody N, et al. Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes. Nature. 2005;436(7049):356–362.
   PubMed Web of Science ®Google Scholar
• Peterson SJ, Husney D, Kruger AL, et al. Long-Term treatment with the apolipoprotein A1 mimetic peptide increases antioxidants and vascular repair in type I diabetic rats. J Pharmacol Exp Ther. 2007;322(2):514–520.
   PubMed Web of Science ®Google Scholar
• Dullaart RP, Otvos JD, James RW. Serum paraoxonase-1 activity is more closely related to HDL particle concentration and large HDL particles than to HDL cholesterol in type 2 diabetic and non-diabetic subjects. Clin Biochem. 2014;47(12):1022–1027.
   PubMed Web of Science ®Google Scholar
• Westerterp M, Gautier EL, Ganda A, et al. Cholesterol accumulation in dendritic cells links the inflammasome to acquired immunity. Cell Metab. 2017;25(6):1294–1304.e6.
   PubMed Web of Science ®Google Scholar
• Vilahur G. High-density lipoprotein benefits beyond the cardiovascular system: a potential key role for modulating acquired immunity through cholesterol efflux. Cardiovasc Res. 2017;113(13):e51–e53.
   PubMed Web of Science ®Google Scholar
• Tiniakou I, Drakos E, Sinatkas V, et al. High-density lipoprotein attenuates Th1 and th17 autoimmune responses by modulating dendritic cell maturation and function. J Immunol. 2015;194(10):4676–4687.
   PubMed Web of Science ®Google Scholar
• Libby P, Buring JE, Badimon L, et al. Atherosclerosis. Nat Rev Dis Primers. 2019;5(1):56.
   PubMed Web of Science ®Google Scholar
• Ibanez B, Giannarelli C, Cimmino G, et al. Recombinant HDLMilano exerts greater anti-inflammatory and plaque stabilizing properties than HDL wild-type. Atherosclerosis. 2012;220(1):72–77.
   PubMed Web of Science ®Google Scholar
• van Stee MF, de Graaf AA, Groen AK. Actions of metformin and statins on lipid and glucose metabolism and possible benefit of combination therapy. Cardiovasc Diabetol. 2018;17(1):94
   PubMed Web of Science ®Google Scholar
• Phielix E, Szendroedi J, Roden M. The role of metformin and thiazolidinediones in the regulation of hepatic glucose metabolism and its clinical impact. Trends Pharmacol Sci. 2011;32(10):607–616.
   PubMed Web of Science ®Google Scholar
• Nicholls SJ, Lundman P, Harmer JA, et al. Consumption of saturated fat impairs the anti-Inflammatory properties of High-Density lipoproteins and endothelial function. J Am Coll Cardiol. 2006;48(4):715–720.
   PubMed Web of Science ®Google Scholar
• Roberts CK, Ng C, Hama S, et al. Effect of a short-term diet and exercise intervention on inflammatory/anti-inflammatory properties of HDL in overweight/obese men with cardiovascular risk factors. J Appl Physiol (1985). 2006;101(6):1727–1732.
   PubMed Web of Science ®Google Scholar
• Sang H, Yao S, Zhang L, et al. Walk-Run training improves the anti-Inflammation properties of High-Density lipoprotein in patients with metabolic syndrome. J Clin Endocrinol Metab. 2015;100(3):870–879.
   PubMed Web of Science ®Google Scholar